AMLX AMYLYX PHARMACEUTICALS INC revenue, earnings and financials

For the quarter ended June 30, 2026, AMYLYX PHARMACEUTICALS INC reported revenue of n/a, net income of −$43.4M and diluted EPS of −$0.39; for the fiscal year ended December 2025 revenue was $0, down 100.0% on the year before.

AMLX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$153M, net income −$145M (margin n/a), EPS −$1.53
• Fiscal year ended Dec 2024: revenue $87.4M, gross profit n/a, operating income −$315M, net income −$302M (margin -345.4%), EPS −$4.43
• Fiscal year ended Dec 2023: revenue $381M, gross profit n/a, operating income $38.8M, net income $49.3M (margin 12.9%), EPS $0.70
• Fiscal year ended Dec 2022: revenue $22.2M, gross profit n/a, operating income −$201M, net income −$198M (margin -892.4%), EPS −$3.39
• Fiscal year ended Dec 2021: revenue $285K, gross profit n/a, operating income −$82.7M, net income −$87.9M (margin -30853.0%), EPS −$13.35

AMLX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$43.4M, EPS −$0.39
• Quarter ended Mar 31, 2026: revenue n/a, net income −$41.3M, EPS −$0.37
• Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (up 100.0% year over year), net income −$33.0M, EPS −$0.28
• Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$34.4M, EPS −$0.37
• Quarter ended Jun 30, 2025: revenue $0 (up 100.0% year over year), net income −$41.4M, EPS −$0.46
• Quarter ended Mar 31, 2025: revenue $0 (down 100.0% year over year), net income −$35.9M, EPS −$0.42
• Quarter ended Dec 31, 2024 (from the annual report): revenue −$665K (down 100.6% year over year), net income −$37.5M, EPS −$0.54
• Quarter ended Sep 30, 2024: revenue $416K (down 99.6% year over year), net income −$72.7M, EPS −$1.07
• Quarter ended Jun 30, 2024: revenue −$1.02M (down 101.0% year over year), net income −$72.7M, EPS −$1.07
• Quarter ended Mar 31, 2024: revenue $88.6M (up 24.1% year over year), net income −$119M, EPS −$1.75
• Quarter ended Dec 31, 2023 (from the annual report): revenue $108M, net income $4.73M, EPS $0.07
• Quarter ended Sep 30, 2023: revenue $103M (up 29666.1% year over year), net income $20.9M, EPS $0.30
• Quarter ended Jun 30, 2023: revenue $98.2M, net income $22.1M, EPS $0.31
• Quarter ended Mar 31, 2023: revenue $71.4M, net income $1.57M, EPS $0.02
• Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$42.7M, EPS −$0.61
• Quarter ended Sep 30, 2022: revenue $345K (up 21.1% year over year), net income −$53.8M, EPS −$0.92
• Quarter ended Jun 30, 2022: revenue n/a, net income −$54.1M, EPS −$0.93
• Quarter ended Mar 31, 2022: revenue n/a, net income −$47.8M, EPS −$0.93
• Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$28.3M, EPS −$4.19
• Quarter ended Sep 30, 2021: revenue $285K, net income −$23.1M, EPS −$3.42

AMLX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$123M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$168M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow $11.9M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$180M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$74.8M, share buybacks n/a

AMLX balance sheet

• Jun 30, 2026: cash $49.3M, total assets $265M, total liabilities $25.4M, shareholders' equity $239M
• Mar 31, 2026: cash $229M, total assets $294M, total liabilities $20.4M, shareholders' equity $273M
• Dec 31, 2025: cash $227M, total assets $333M, total liabilities $27.4M, shareholders' equity $305M
• Sep 30, 2025: cash $225M, total assets $363M, total liabilities $30.7M, shareholders' equity $332M
• Jun 30, 2025: cash $58.1M, total assets $195M, total liabilities $26.7M, shareholders' equity $168M
• Mar 31, 2025: cash $59.8M, total assets $220M, total liabilities $18.3M, shareholders' equity $201M
• Dec 31, 2024: cash $77.4M, total assets $194M, total liabilities $28.9M, shareholders' equity $165M
• Sep 30, 2024: cash $71.8M, total assets $251M, total liabilities $54.5M, shareholders' equity $196M

What is AMLX's revenue?

AMYLYX PHARMACEUTICALS INC reported $0 of revenue for the fiscal year ended December 2025.

Is AMLX profitable?

No. AMYLYX PHARMACEUTICALS INC lost $152M over the last four quarters.

What is AMLX's EPS?

Diluted earnings per share over the last four quarters were −$1.41; −$0.39 in the latest quarter.

AMLX ownership and insider trades · All stocks